Skip to main content

Advertisement

SpringerLink
Log in

Die Wahl der Chemotherapie unter einer PET-CT-geführten Therapiedeeskalation hat einen signifikanten Einfluss auf die Fertilität und Lebensqualität junger Hodgkin-Patientinnen und Patienten

The choice of chemotherapy under PET/CT-guided treatment de-escalation has a significant impact on fertility and quality of life in young Hodgkin’s lymphoma patients

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Øvlisen AK et al (2021) Parenthood rates and use of assisted reproductive techniques in younger Hodgkin lymphoma survivors: a Danish population-based study. J Clin Oncol 39:3463–3472

    Article  Google Scholar 

  2. Gallamini A et al (2007) Early interim 2‑[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752

    Article  CAS  Google Scholar 

  3. Carde P et al (2016) Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPP baseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol 34:2028–2036

    Article  CAS  Google Scholar 

  4. Scorsetti M et al (2020) Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiat Oncol 15:12

    Article  Google Scholar 

  5. Casasnovas R‑O et al (2019) PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 20:202–215

    Article  Google Scholar 

  6. Merli F et al (2016) Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 34:1175–1181

    Article  CAS  Google Scholar 

  7. Rosenbrock J et al (2022) Volumetric modulated arc therapy versus intensity-modulated proton therapy in the irradiation of infra diaphragmatic Hodgkin lymphoma in female patients. Acta Oncol 61:81–88

    Article  CAS  Google Scholar 

  8. Skoetz N et al (2017) Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 5:CD7941

    PubMed  Google Scholar 

  9. Amin MSA et al (2021) ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma. Clin Transl Oncol 23:1067–1077

    Article  CAS  Google Scholar 

  10. Diehl V et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395

    Article  CAS  Google Scholar 

  11. Behringer K et al (2005) Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 23:7555–7564

    Article  Google Scholar 

  12. Borchmann P et al (2017) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390:2790–2802

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Radio-Onkologie, Universitätsspital Zürich, Universität Zürich, Rämistrasse 100, 8091, Zürich, Schweiz

    Ricarda Stella Guninski &  Panagiotis Balermpas

Authors
  1. Ricarda Stella Guninski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panagiotis Balermpas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panagiotis Balermpas.

Ethics declarations

Interessenkonflikt

R.S. Guninski und P. Balermpas geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Casasnovas R‑O et al (2019) PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL 2011): a randomised, multicentre, non-inferiority, phase III study. Lancet Oncol 20:202–215.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guninski, R.S., Balermpas, P. Die Wahl der Chemotherapie unter einer PET-CT-geführten Therapiedeeskalation hat einen signifikanten Einfluss auf die Fertilität und Lebensqualität junger Hodgkin-Patientinnen und Patienten. Strahlenther Onkol 198, 752–754 (2022). https://doi.org/10.1007/s00066-022-01946-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-022-01946-x

Search

Navigation